Michael Mcinaw serves as Executive at Aevi Genomic Medicine, Inc., where they oversee executive responsibilities. Since joining the company, Michael Mcinaw has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 3, 2020 involved selling 16,107 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Feb 3, 2020 | GNMX | $0 | Disposition | 16,107 | $N/A | Discretionary |
Michael Mcinaw currently holds 16,107 shares of Aevi Genomic Medicine, Inc. (GNMX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Michael Mcinaw has been a net neutral trader of GNMX stock. They have purchased $0 and sold $0 worth of shares.
Michael Mcinaw's most recent insider trade was on Feb 3, 2020, when they sold 16,107 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted